Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORα

Circulation

Volumn 98, Issue 24, 1998, Pages 2738-2743

  Mamontova, Anna ^a   Séguret Macé, Sandrine ^b   Esposito, Bruno ^a   Chaniale, Colette ^c   Bouly, Muriel ^d   Delhaye Bouchaud, Nicole ^e   Luc, Gérald ^d   Staels, Bart ^d   Duverger, Nicolas ^b   Mariani, Jean ^e   Tedgui, Alain ^a  

^a INSERM   (France)

^b SANOFI   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Apolipoproteins; Cholesterol; Genes; Hypercholesterolemia

Indexed keywords

CELL NUCLEUS RECEPTOR; CHOLESTEROL; LIPOPROTEIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG RECEPTOR BINDING; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HOMOZYGOSITY; HYPERCHOLESTEROLEMIA; HYPOLIPOPROTEINEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0345698769     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.24.2738     Document Type: Article

References (42)

1. Genest JJ Jr, Martin-Munley SS, McMamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-2033.
2. Dammerman M, Breslow JL. Genetic basis of lipoprotein disorders. Circulation. 1995;91:505-512.
3. Gordon T, Castelli WP, Hjortland MC, Kannel WB. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714.
4. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr. Bangdiwala S, Tyroler A. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
5. Reichl D, Miller NE. Pathophysiology of reverse cholesterol transport: insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis. 1989;9:785-797.
6. Breslow JL. Familial disorders of high density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Spy WS, Valle D, ed. The Metabolic Basis of Inherited Disease. 6th ed. New York. NY: McGraw-Hill: 1989;1: 1251-1266.
7. Schaefer EJ, McNamara JR, Genest J Jr, Ordovas JM. Genetics and abnormalities in metabolism of lipoproteins. In: Miller NE, ed. High Density Lipoproteins and Atherosclerosis. New York. NY: Elsevier Science Publishing Co Inc; 1989;79-86.
8. Sidman RL, Lane PV, Dickie MM. Staggerer, a new mutation in the mouse affecting the cerebellum. Science. 1962;136:610-612.
9. Herrup K, Müllen RJ. Regional variation and absence of large neurons in the cerebellum of the staggerer mouse. Brain Res. 1979;172:1-12.
10. Shojaeian-Zanjani H, Herrup K, Guastavino JM, Delhaye-Bouchaud N, Mariani J. Developmental studies of the inferior olivary nucleus in staggerer mutant mice. Dev Brain Res. 1994;82:18-28.
11. Trenkner E, Hoffmann MK. Defective development of the thymus and immunological abnormalities in the neurological mouse mutation staggerer. J Neurosci. 1986;6:1733-1737.
12. Kopmels B, Mariani J, Delhaye-Bouchaud N, Audibert F, Fradelizi D, Wollman EE. Evidence for a hyperexcitability state of staggerer mutant mice macrophages. J Neurochem. 1992;58:192-199.
13. Hamilton BA, Frankel WN, Kerrebrock AW, Hawkins TL, FitzHugh W, Kusumi K, Russell LB, Mueller KL, van Berkel V, Birren BW, Kruglyak L, Lander ES. Disruption of the nuclear hormone receptor RORα in staggerer mice. Nature. 1996;379:736-739.
14. Giguère V, Tini M, Flock G, Ong E, Evans RM, Otulakowski G. Isoform-specific amino-terminal domains dictate DNA-binding properties of RORα, a novel family of orphan hormone nuclear receptors. Genes Dev. 1994;8:538-553.
15. Becker-André M, André E, DeLamarter JF. Identification of nuclear receptor mRNAs by RT-PCR amplification of conserved zinc-finger motif sequences. Biochem Biophys Res Commun. 1993;194:1371-1379.
16. Carlberg C, van Huijsduijnen R, Staple JK, DeLamarter JF, Becker-André M. RZRs, a new family of retinoid-related orphan receptors that function as both monomers and homodimers. Mol Endocrinol. 1994;8:757-770.
17. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995;83:841-850.
18. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37:907-925.
19. Tzameli I, Zannis VI. Binding specificity and modulation of the apoA-I promoter activity by homo- and heterodimers of nuclear receptors. J Biol Chem. 1996;271:8402-8415.
20. Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis. 1990;10:316-323.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
22. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, Fruchart JC, Rubin E, Denefle P, Staels B, Branellec D. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest. 1996;97: 2408-2416.
23. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density iipoprotein proteins, I: preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972;260:212-221.
24. Nishina PM, Wang J, Toyofuku W, Kuypers FA, Ishida BY. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids. 1993;28:599-605.
25. Paigen B, Holmes PA, Mitchell D, Albee D. Comparison of atherosclerosis lesions and HDL-lipid levels in male, female, and testosterone-treated female mice from C57BL/6, BALB/c, and CH3. Atherosclerosis. 1987;64:215-221.
26. Paigen B, Mitchel D, Reue K, Morrow A, Lusis AJ, LeBoeuf RC. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein level in mice. Proc Natl Acad Sci USA. 1987;84:3763-3767.
27. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
28. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein Al transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899-903.
29. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91:9607-9611.
30. Duverger ND, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro G, Tailleux A, Fievet C, Fruchart JM, Houdebine LM, Denefle P. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I transgenic rabbits. Circulation. 1996;94:713-719.
31. Li H, Reddick RL, Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb. 1993;13:1814-1821.
32. Takata K, Saku K, Ohta T, Takata M, Bai H, Jimi S, Liu R, Sato H, Kajiyama G, Arakawa K. A new case of apoA-I deficiency showing codon 8 nonsense mutation of the apoA-I gene without evidence of coronary heart disease. Arterioscler Thromb Vasc Biol. 1995;15: 1866-1874.
33. Vu-Dac N, Gervois P, Grötzinger T, De Vos P, Schoonjans K, Fruchart J-C, Auwerx J, Mariani J, Tedgui A, Staels B. Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor RORα. J Biol Chem. 1997;272:22401-22404.
34. Staels B, Auwerx J, Chan L, van Tol A, Rosseneu M, Verhoeven G. Influence of development, estrogens and food intake on apolipoprotein A-I, A-II and E mRNA in the rat liver and intestine. J Lipid Res. 1989;30:1137-1145.
35. Staels B, Van Tol A, Andreu T, Auwerx J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb. 1992;12:286-294.
36. Berthou L, Staels B, Saldicco I, Berthelot I, Casey J, Fruchart J-C, Denèfle P, Branellec D. Opposite in vitro and in vivo regulation of hepatic apolipoprotein A-I gene expression by retinoic acid: absence of effects on apolipoprotein A-II gene expression. Arterioscler Thromb. 1994;14:1657-1664.
37. Liao F, Andalibi A, deBeer FC, Fogelman AM, Lusis AJ. Genetic control of inflammatory gene induction and NF-κB-like transcription factor activation in response to atherogenic diet in mice. J Clin Invest. 1993;91: 2572-2579.
38. Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest. 1994;94:877-884.
39. Missbach M, Jagher B, Sigg I, Nayeri S, Carlberg C, Wiesenberg I. Thiazolidine diones, specific ligands of the nuclear receptor retinoid Z receptor/retinoid acid receptor-related orphan receptor a with potent antiarthritic activity. J Biol Chem. 1996;271:13515-13522.
40. Becker-André M, Wiesenberg I, Schaeren-Wiemers N, André E, Missbach M, Saurat J-H, Carlberg C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem. 1994;269:28531-28534.
41. Wiesenberg I, Missbach M, Kahlen J-P, Schräder M, Carlberg C. Transcriptional activation of the nuclear receptor RZRα by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res. 1995;23:327-333.
42. Steinhilber D, Brungs M, Werz O, Wiesenberg I, Danielsson C, Kahlen J-P, Nayeri S, Schräder M, Carlberg C. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem. 1995;270:7037-7040.